K2Quest® (Vitamin K2 as MK-7)

Evidence Level
Preliminary
0 Clinical Trials
4 Documented Benefits
1/5 Evidence Score

K2Quest® is a branded vitamin K2 as menaquinone-7 (MK-7) listed by the US supplier NutriScience Innovations. Its 2018 launch report described it as a synthetic MK-7 in oil, while the current supplier listing says it is available in fermented, synthetic, oil and powder forms, so the production method of a given product is unclear. No published human trial of K2Quest itself was found. Like other MK-7, it is the cofactor that activates osteocalcin in bone and matrix Gla protein in vessel walls, and MK-7 has an elimination half-life of about 3 days. Trials of other MK-7 products disagree on bone density: 1 year of 90 mcg a day slowed femoral neck loss in Chinese postmenopausal women, while Danish and Norwegian trials found no difference from placebo. Those trials, and the MenaQ7 bone and artery stiffness trial, are described on the vitamin K2 (MK-7) and MenaQ7 pages.

Studied Dose No dose of K2Quest itself has been tested in a published trial. Placebo-controlled bone trials of other MK-7 products used 50 to 375 mcg a day for 1 to 3 years; the MenaQ7 bone trial used 180 mcg a day.
Active Compound Menaquinone-7 (MK-7), vitamin K2; described at its 2018 launch as a synthetic MK-7 in oil; the current supplier listing names fermented and synthetic forms in powder and oil.

Benefits

Bone density with other MK-7 products

No bone trial tested K2Quest. With other MK-7 products, 90 mcg a day for 1 year slowed femoral neck loss in Chinese postmenopausal women but not in men; 375 mcg a day preserved shin bone structure at 1 year but not density at 3 years in Danish women; and 360 mcg a day as natto capsules did not change bone loss in Norwegian women over 1 year.

Artery stiffness with other MK-7 products

No vascular trial tested K2Quest. In 96 adults on hemodialysis, 375 mcg of MK-7 a day for 24 weeks did not change carotid-femoral pulse wave velocity, the main outcome, compared with standard care in an open-label design. The 3-year MenaQ7 trial in healthy postmenopausal women that lowered pulse wave velocity is described on the MenaQ7 page.

Osteocalcin and matrix Gla protein activation

In 200 adults on hemodialysis, 360, 720 or 1080 mcg of MK-7 three times a week for 8 weeks lowered inactive matrix Gla protein by 17, 33 and 46%, with no placebo group. In placebo-controlled bone trials of other MK-7 products, undercarboxylated osteocalcin fell. These are blood markers, not health outcomes.

Long half-life and steady blood levels

MK-7 has an elimination half-life of about 3 days, compared with 1 to 2 hours for vitamin K1, and it accumulated 7- to 8-fold during prolonged daily intake. These are blood-level findings for MK-7 in general, not health outcomes.

Mechanism of action

1

Gamma-carboxylation of Gla-domain proteins

Vitamin K is the cofactor for gamma-glutamyl carboxylase, the enzyme that converts glutamate residues on osteocalcin, matrix Gla protein and the clotting factors into calcium-binding gamma-carboxyglutamate. Without enough vitamin K these proteins circulate in an undercarboxylated, less active form.

2

Osteocalcin activation in bone

Carboxylated osteocalcin binds the mineral of bone, and the undercarboxylated form is used as a blood marker of low vitamin K status. MK-7 reliably lowers undercarboxylated osteocalcin in trials, but in some of them bone density did not change, so the marker shift does not by itself show a bone benefit.

3

Matrix Gla protein in vessel walls

Carboxylated matrix Gla protein restrains calcium deposition in soft tissue, and its inactive form (dp-ucMGP) is used as a blood marker. MK-7 lowered dp-ucMGP in the vascular trials that measured it, yet calcification on scans did not change in some of them, so the marker is not proof of less calcification.

4

Long half-life of the long-chain form

MK-7 has an elimination half-life of about 3 days, while vitamin K1 lasts 1 to 2 hours and MK-4 falls to near zero within 24 hours. In a comparison study MK-7 also gave more complete osteocalcin carboxylation than vitamin K1.

Clinical trials

Side effects and drug interactions

Common Potential side effects

A US Pharmacopeia safety review concluded that MK-7 taken as a dietary supplement 'is not associated with any serious risk to health'; that review covered data up to 2017.
A review of vitamin K safety reported almost no cases of systemic toxicity from natural vitamin K in animals or people.
No serious adverse events were observed in a 24-week trial of 375 mcg MK-7 a day in adults on hemodialysis.
In an 8-week dose-finding study in adults on hemodialysis, dropouts were mainly due to digestive side effects linked to the unpleasant smell of the MK-7 tablets.
The main risk is for people taking warfarin or another vitamin K antagonist: MK-7 at 50 mcg a day or more may interfere with these drugs (see Drug Interactions).
No trial cited on this page enrolled pregnant or breastfeeding women; ask a clinician before taking supplement doses during pregnancy or breastfeeding.

Important Drug interactions

Warfarin and other vitamin K antagonists: vitamin K counteracts these drugs, and researchers comparing supplement forms warned that 50 mcg a day or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way. Do not start, stop or change MK-7 without the clinic that manages your dose.
Cholestyramine can reduce vitamin K absorption, likely by binding bile acids.
Orlistat causes digestive side effects with fatty meals, so people taking it tend to eat less fat, which can lower absorption of fat-soluble vitamin K.
Rifampicin can reduce vitamin K levels by speeding up its metabolism.
Broad-spectrum antibiotics can suppress gut bacteria that make vitamin K and raise the risk of vitamin K deficiency.

Frequently asked questions about K2Quest® (Vitamin K2 as MK-7)

What is K2Quest?

K2Quest® is a branded vitamin K2 as menaquinone-7 (MK-7) listed by the US supplier NutriScience Innovations. Its 2018 launch report described it as a synthetic MK-7 in oil, while the current supplier listing says it is available in fermented, synthetic, oil and powder forms, so the production method of a given product…

What is K2Quest used for?

NutraSmarts does not list K2Quest under a health category. What the research covers: No bone trial tested K2Quest. With other MK-7 products, 90 mcg a day for 1 year slowed femoral neck loss in Chinese postmenopausal women but not in men; 375 mcg a day preserved shin bone structure at 1 year but not density at 3 years in Dan…

What is the recommended dosage of K2Quest?

No dose of K2Quest itself has been tested in a published trial. Placebo-controlled bone trials of other MK-7 products used 50 to 375 mcg a day for 1 to 3 years; the MenaQ7 bone trial used 180 mcg a day. Always follow the product label and check with a healthcare provider for personal advice.

Is K2Quest safe, and does it have side effects?

Side effects and cautions reported for K2Quest include: A US Pharmacopeia safety review concluded that MK-7 taken as a dietary supplement 'is not associated with any serious risk to health'; that review covered data up to 2017. It may also interact with some medications. K2Quest is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does K2Quest interact with any medications?

Possible interactions include: Warfarin and other vitamin K antagonists: vitamin K counteracts these drugs, and researchers comparing supplement forms warned that 50 mcg a day or more of MK-7 may interfere with oral anticoagulant treatment in a clinically relevant way. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for K2Quest?

NutraSmarts rates the evidence for K2Quest as Preliminary (1 out of 5). It is backed by 13 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(13 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-507. doi: 10.1007/s00198-013-2325-6.PubMedUsed to support: Other product: this trial tested MenaQ7 (the study was funded by NattoPharma, the MenaQ7 maker, and the companion stiffness report names MenaQ7), so it is listed here only for context; see the MenaQ7 page. In 244 healthy postmenopausal women, 180 mcg a day for 3 years improved vitamin K status and decreased the age-related decline in bone mineral content and density at the lumbar spine and femoral neck, but not at the total hip. The abstract does not name a single primary outcome.
  2. Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015;113(5):1135-44. doi: 10.1160/TH14-08-0675.PubMedUsed to support: Other product: MenaQ7, 180 mcg a day for 3 years in the same 244 healthy postmenopausal women as the bone report; see the MenaQ7 page. Carotid-femoral pulse wave velocity and the stiffness index beta decreased in the whole group; other vessel measures improved only in women with stiffer arteries at baseline. dp-ucMGP fell 50% versus placebo; inflammation and endothelial markers did not change. An imaging measure, not heart events.
  3. Zhang Y, Liu Z, Duan L, Ji Y, Yang S, Zhang Y, Li H, Wang Y, Wang P, Chen J, Li Y. Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study. Calcif Tissue Int. 2020;106(5):476-485. doi: 10.1007/s00223-020-00669-4.PubMedUsed to support: Not a K2Quest study (another MK-7 product; see the vitamin K2 (MK-7) page). Randomized, placebo-controlled 1-year trial in 311 Chinese adults aged 50 to 75 (placebo, 50 mcg, 90 mcg, or 90 mcg with calcium and vitamin D3): femoral neck bone loss was lower than placebo in postmenopausal women in both 90 mcg groups (p = 0.006), with no effect in men and no added effect from calcium and vitamin D3. The article keywords list menaquinone-7; government funded, no conflicts declared.
  4. Rønn SH, Harsløf T, Pedersen SB, Langdahl BL. Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. Eur J Endocrinol. 2016;175(6):541-549. doi: 10.1530/EJE-16-0498.PubMedUsed to support: Not a K2Quest study (another MK-7 product; see the vitamin K2 (MK-7) page). 1-year report of a randomized, double-blind, placebo-controlled trial of MK-7 375 mcg a day in 148 postmenopausal women with osteopenia, all also taking calcium and vitamin D. Tibia trabecular number, spacing and thickness were preserved versus placebo (P < 0.05), but radius structure and bone mineral density at any site did not differ. MK-7 supplied by Orkla Health according to the 3-year report.
  5. Rønn SH, Harsløf T, Oei L, Pedersen SB, Langdahl BL. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. Osteoporos Int. 2021;32(1):185-191. doi: 10.1007/s00198-020-05638-z.PubMedUsed to support: Not a K2Quest study (another MK-7 product; see the vitamin K2 (MK-7) page). 3-year report of the same Danish trial (142 women, 375 mcg a day, with calcium and vitamin D in both groups): areal bone mineral density fell at all sites with no difference between MK-7 and placebo (p > 0.09), and turnover markers and microstructure changes were similar. Orkla Health gave financial support and supplied the MK-7. The 1-year structure gain did not persist.
  6. Emaus N, Gjesdal CG, Almås B, Christensen M, Grimsgaard AS, Berntsen GK, Salomonsen L, Fønnebø V. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int. 2010;21(10):1731-40. doi: 10.1007/s00198-009-1126-4.PubMedUsed to support: Not a K2Quest study (another MK-7 product; see the vitamin K2 (MK-7) page). Randomized, double-blind, placebo-controlled trial in 334 healthy Norwegian women 1 to 5 years after menopause: 360 mcg MK-7 a day as natto capsules for 12 months did not change bone loss rates at the total hip or any other site, while carboxylated osteocalcin rose and undercarboxylated osteocalcin fell (p < 0.001). Study medication provided by NATURAL per the article page; MK-7 not from the MenaQ7 maker as far as stated.
  7. Caluwé R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014;29(7):1385-90. doi: 10.1093/ndt/gft464.PubMedUsed to support: Not a K2Quest study (another MK-7 product, not named in the abstract). Randomized dose-finding study without a placebo group in 200 adults on chronic hemodialysis: 360, 720 or 1080 mcg MK-7 three times a week for 8 weeks lowered dp-ucMGP by 17, 33 and 46%. Dropouts were mainly due to digestive side effects related to the unpleasant smell of the tablets. A blood marker study, not a health outcome trial.
  8. Naiyarakseree N, Phannajit J, Naiyarakseree W, Mahatanan N, Asavapujanamanee P, Lekhyananda S, Vanichakarn S, Avihingsanon Y, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial. Nutrients. 2023;15(11):2422. doi: 10.3390/nu15112422.PubMedUsed to support: Not a K2Quest study (another MK-7 product, not named in the abstract). Open-label multicenter randomized trial in 96 hemodialysis patients with high arterial stiffness: 375 mcg MK-7 a day for 24 weeks versus standard care did not change carotid-femoral pulse wave velocity, the primary outcome (p = 0.24); a difference appeared only in the subgroup with diabetes. No serious adverse events were observed. The authors declared no conflicts.
  9. Schurgers LJ, Teunissen KJ, Hamulyák K, Knapen MH, Vik H, Vermeer C. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-83. doi: 10.1182/blood-2006-08-040709.PubMedUsed to support: Comparison in healthy volunteers of synthetic vitamin K1 and natto-derived MK-7 supplements (the abstract does not name the MK-7 product). Both peaked in serum 4 hours after intake; MK-7 had a very long half-life, more stable serum levels and 7- to 8-fold accumulation during prolonged intake, and gave more complete osteocalcin carboxylation. The authors warned that 50 mcg a day or more of MK-7 may interfere with oral anticoagulant treatment. Blood-level and marker study, not a health-outcome trial.
  10. Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, Protti M, Remião F, Nováková L, OEMONOM researchers and collaborators. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev. 2022;80(4):677-698. doi: 10.1093/nutrit/nuab061.PubMedUsed to support: Review of vitamin K kinetics and safety. States that MK-7 has an elimination half-life of about 3 days versus 1 to 2 hours for vitamin K1, that MK-4 levels drop to near zero 24 hours after a dose, that cholestyramine, rifampicin and orlistat can reduce vitamin K absorption or levels, that broad-spectrum antibiotics can raise the risk of vitamin K deficiency, and that almost no cases of natural vitamin K systemic toxicity have been reported. Source for the half-life, interaction and toxicity statements on this page.
  11. Marles RJ, Roe AL, Oketch-Rabah HA. US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K. Nutr Rev. 2017;75(7):553-578. doi: 10.1093/nutrit/nux022.PubMedUsed to support: US Pharmacopeia safety evaluation of MK-7 covering chemistry, intake, pharmacokinetics, animal toxicity and adverse events in clinical studies. It concluded that MK-7 ingested as a dietary supplement 'is not associated with any serious risk to health or with other public health concerns' and developed USP quality monographs on that basis. Scope: data reviewed up to 2017.
  12. Menayang A. XSTO Solutions launches branded vitamin K ingredient K2Quest NutraIngredients. 2018;Published 19 September 2018..SourceUsed to support: Trade press report, not PubMed-indexed. Reports the 2018 launch of K2Quest by the New Jersey supplier XSTO Solutions and describes it as a synthetic vitamin K that comes in oil form. It names no clinical trial of K2Quest.
  13. Nutriscience Innovations LLC. K2Quest product listing Ingredients Network. 2026;Supplier listing, accessed November 2026..SourceUsed to support: Supplier listing, not PubMed-indexed. Names Nutriscience Innovations as the supplier, states K2Quest is available in powder and oil forms, and says it is available in many forms of MK-7: fermented, synthetic, oil and powder. Its references to clinical science name no K2Quest trial.